Ophirex, Inc. has been awarded a firm fixed price definitive contract valued at $1,299,779 by the Department of the Army Medical Command. This contract is a Small Business Innovation Research Program Phase II award to further develop Ophirex's intravenous snakebite antidote varespladib. Specifically, the contract aims to improve recovery time following snakebite through metalloprotease inhibition. As a total small business set aside, this award will support Ophirex's continued medical research and development efforts toward a broad-spectrum treatment for snakebite envenomation. Work will be performed by Ophirex in Corte Madera, California through the projected period of performance completion date of December 2025.
Generated 1/29/24, 9:17 AM